Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
11/1999
11/23/1999US5989828 Binding to matrix; vaccines
11/23/1999US5989805 Immortal avian cell line to grow avian and animal viruses to produce vaccines
11/23/1999US5989804 E6 binding proteins
11/23/1999US5989803 Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
11/23/1999US5989564 Pertussis toxoid made by reacting pertussis toxin with the nitrating agent TNM
11/23/1999US5989563 Viral agent associated with mystery swine disease
11/23/1999US5989562 Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
11/23/1999US5989561 Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses
11/23/1999US5989556 Compositions of matter useful in the treatment of viral infections derived from plant extracts
11/23/1999US5989555 Extracts of Larrea tridentata having antiviral activity and their use for treating viral infections
11/23/1999US5989548 Peptide-based composition against papillomavirus infection
11/23/1999US5989547 Leptospiral outer membrane proteins
11/23/1999US5989542 Capsular polysaccharides from enterococci
11/23/1999US5989522 Anti-mycotic drug and ethyl cellulose to provide sustained release
11/23/1999CA2001167C Substituted 2-aminothiazoles
11/23/1999CA1340825C Hyaluronic acid fraction for use as a drug delivery system for medicaments
11/18/1999WO1999058706A1 Novel method for preparing synthesis intermediates
11/18/1999WO1999058684A2 Compounds from moraxella catarrhalis
11/18/1999WO1999058683A2 BASB029 POLYNUCLEOTIDE(S) AND POLYPEPTIDES FROM $i(NEISSERIA MENINGITIDIS)
11/18/1999WO1999058678A2 Antibodies to dendritic cells and human dendritic cell populations and uses thereof
11/18/1999WO1999058658A2 Expression vectors for stimulating an immune response and methods of using the same
11/18/1999WO1999058642A2 Secreted proteins and polynucleotides encoding them
11/18/1999WO1999058639A2 Structural proteins of fish pancreatic disease virus and uses thereof
11/18/1999WO1999058541A2 Improvements in macrolide production
11/18/1999WO1999058540A2 1-galactose derivatives
11/18/1999WO1999058536A1 NOVEL β-LACTAM COMPOUNDS AND PROCESS FOR PRODUCING THE SAME
11/18/1999WO1999058535A1 Novel cephalosporin compounds, processes for preparation thereof and antimicrobial compositions containing the same
11/18/1999WO1999058531A1 Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
11/18/1999WO1999058530A1 Water soluble azoles as broad-spectrum antifungals
11/18/1999WO1999058529A1 Water soluble azoles as broad-spectrum antifungals
11/18/1999WO1999058528A1 Substituted aryl hydroxamic acids as metalloproteinase inhibitors
11/18/1999WO1999058523A1 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
11/18/1999WO1999058512A1 Morpholino ethers
11/18/1999WO1999058505A2 Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer
11/18/1999WO1999058502A1 Heterocyclic inhibitors of p38
11/18/1999WO1999058146A1 ATTENUATED MUTANTS OF SALMONELLA WHICH CONSTITUTIVELY EXPRESS THE Vi ANTIGEN
11/18/1999WO1999058145A2 Immunomodulators for vaccines
11/18/1999WO1999058143A1 Utilization of interferon alpha 5 in the treatment of viral hepatopathies
11/18/1999WO1999058141A1 Indolicidin analogs and methods of using same
11/18/1999WO1999058137A1 Bio-pharmaceutical preparation containing a live culture of bacillus and method for treating viral and bacterial infections as well as immuno-deficiency conditions
11/18/1999WO1999058129A1 Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
11/18/1999WO1999058110A1 Mucoadhesive compositions for administration of biologically active agents to animal tissue
11/18/1999WO1999058096A2 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
11/18/1999WO1999052562A3 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
11/18/1999WO1999051202A3 Quinolone containing liposomes and their use as antibacterial agents
11/18/1999WO1999049888A3 Identification of bacterial avirulence genes and their products; vaccines and pharmaceutical compositions containing them
11/18/1999WO1999046283A9 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
11/18/1999WO1999042076A9 Compounds and methods for immunotherapy and diagnosis of tuberculosis
11/18/1999WO1999028475A3 Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
11/18/1999WO1999027098A3 A-33 related antigens and their pharmacological uses
11/18/1999DE19822036A1 Effervescent pharmaceutical composition with improved stability
11/18/1999CA2685270A1 Expression vectors for stimulating an immune response and methods of using the same
11/18/1999CA2331878A1 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors
11/18/1999CA2331832A1 E.coli heat-labile enterotoxin subunit b (etxb) as an immunomodulator
11/18/1999CA2331586A1 Novel .beta.-lactam compounds and process for producing the same
11/18/1999CA2331584A1 Morpholino ethers
11/18/1999CA2331350A1 Mucoadhesive compositions for administration of biologically active agents to animal tissue
11/18/1999CA2331315A1 Identification of molecular interaction sites in rna for novel drug discovery
11/18/1999CA2331295A1 Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer
11/18/1999CA2330484A1 1-galactose derivatives
11/18/1999CA2330108A1 Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
11/18/1999CA2330095A1 Substituted aryl hydroxamic acids as metalloproteinase inhibitors
11/18/1999CA2328965A1 Novel cephalosporin compounds, processes for preparation thereof and antimicrobial compositions containing the same
11/18/1999CA2328502A1 Cloning of basb020 antigen from moraxella catarrhalis
11/18/1999CA2328403A1 Basb029 polynucleotide(s) and polypeptides from neisseria meningitidis
11/18/1999CA2328062A1 Secreted proteins and polynucleotides encoding them
11/18/1999CA2325659A1 Indolicidin analogs and methods of using same
11/18/1999CA2325636A1 Oral medicinal forms with reproducible release of the active ingr edient gatifloxacin or its pharmaceutically acceptable salts or hydrates
11/18/1999CA2288993A1 Bio-pharmaceutical preparation containing a live culture of bacillus and method for treating viral and bacterial infections as well as immuno-deficiency conditions
11/17/1999EP0957101A1 Water soluble azoles as broad-spectrum antifungals
11/17/1999EP0957093A2 Retrovial protease inhibitors
11/17/1999EP0957091A1 Inhibitors of tumor necrosis factor alpha
11/17/1999EP0956861A1 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
11/17/1999EP0956859A1 Antioxidizing composition for scavenging free radicals, pharmaceutical composition comprising the same, and process for preparing the same
11/17/1999EP0956858A1 Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections
11/17/1999EP0956352A1 A polynucleotide herpes virus vaccine
11/17/1999EP0956349A1 Synthetic hpv16 virus-like particles
11/17/1999EP0956343A1 Recombinant swinepox virus
11/17/1999EP0956289A1 Novel prokaryotic polynucleotides, polypeptides and their uses
11/17/1999EP0956046A2 Cellular vaccines and immunotherapeutics and methods for their preparation
11/17/1999EP0956045A2 Assembly-deficient herpesvirus vaccine
11/17/1999EP0956044A1 Uses of a chemokine receptor for inhibiting hiv-1 infection
11/17/1999EP0956043A1 Strain selection of pneumococcal surface proteins
11/17/1999EP0956042A2 Mycosis vaccines
11/17/1999EP0956040A1 Stimulation of host defense mechanisms against viral challenges
11/17/1999EP0956033A1 Total synthesis of the amino hip analogue of didemnin a
11/17/1999EP0956031A1 Inhibition of 26s and 20s proteasome by indanones
11/17/1999EP0956029A1 Cyclic peptides having broad spectrum antimicrobial activity
11/17/1999EP0956021A1 L-$g(b)-DIOXOLANE URIDINE ANALOGS AND METHODS FOR TREATING AND PREVENTING VIRUS INFECTIONS
11/17/1999EP0956017A1 Benzimidazole-2-carbamates for the treatment of viral infections and cancer
11/17/1999EP0956016A1 Pharmaceutical compounds comprising polyamines substituted with electron-affinic groups
11/17/1999EP0738273B1 Monohydrate of (e)-2'-deoxy-2'-(fluoromethylene)cytidine
11/17/1999EP0604566B1 Chimeric and/or growth-restricted flaviviruses
11/17/1999EP0572537B1 Cytokine inhibitors
11/17/1999CN1235609A Immunostimulatory nucleic acid molecules
11/17/1999CN1235608A Alkylated reapamycin derivatives
11/17/1999CN1235602A 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic urea useful as HIV protease inhibitors
11/17/1999CN1235601A (4R,5S,6S,7R)-hexahydro-1-[5-(3-aminoinazole) methyl]-3-butyl-5,6-dihydroxy-4,]-bis [phaenylmethyl]-2H-1,3-diazepin-2-one, its preparation and use as HIV protease inhibitors
11/17/1999CN1235555A Compounds and methods for treatment and diagnosis of mycobacterial infections
11/17/1999CN1235554A Antifungal combination therapy
1 ... 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 ... 1798